Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for May, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Teva Pharmaceutical Industries Ltd. ( TEVA - Analyst Report ) recently announced that it has launched its generic version of Forest Laboratories’ ( FRX - Analyst Report ) Lexapro. Teva will enjoy six months of marketing exclusivity as it was the first generic company to have filed an Abbreviated New Drug Application (ANDA) for Lexapro with a paragraph IV challenge.
Lexapro has been a major revenue generator for Forest Labs with the product generating sales of $1.8 billion in the first nine months of fiscal 2012. Besides Teva’s generic version, Mylan’s ( MYL - Analyst Report ) authorized generic version of Lexapro is available in the market.
Mylan had announced the launch of its authorized generic version in late February 2011. According to its settlement agreement with Forest Labs, Mylan will market its product until the compound patent loses pediatric exclusivity.
Lexapro is indicated for the acute and maintenance treatment of major depressive disorder (MDD) and acute treatment of generalized anxiety disorder. Lexapro sales will be impacted significantly with the entry of Teva’s generic version. The product accounted for 55% of Forest Labs’ total sales in fiscal 2011.
Another key product, Namenda, in Forest Labs’ portfolio could start facing generic competition in early 2015. To reduce the impact of genericization, Forest Labs has been working on developing its pipeline. The company has two important FDA action dates coming up in the second quarter of 2012. While linaclotide (partnered with Ironwood Pharmaceuticals ( IRWD - Snapshot Report ) ) is under review for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation, aclidinium (partnered with Almirall) is under regulatory review for chronic obstructive pulmonary disease (COPD).
Meanwhile, the company expects to file two more new drug applications (NDAs) in the second half of 2012 (levomilnacipran and cariprazine).
We currently have Neutral recommendations on Forest Labs as well as Teva. Both companies carry a Zacks #3 Rank (short-term “Hold’’ rating).
Read the full reports :
Snapshot Report on IRWD
Analyst Report on FRX
Analyst Report on TEVA
Analyst Report on MYL